Stryker Corporation (SYK) fair value analysis

S&P 500 · Updated 2026-09-07

Stryker Corporation is a medical technology company that manufactures and sells orthopedic implants, surgical instruments, medical devices, and software systems used in operating rooms and patient care settings. The company operates globally, serving hospitals, surgical centers, and healthcare providers across North America, Europe, Asia-Pacific, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, SYK is trading at more than a 25% discount to estimated fair value.

SYK currently ranks #21 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $303.13
Sector: Healthcare
12-month range: $294.73–$387.02

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Moderate
Margin trend: Stable
Revenue growth: Strong
RSI zone: Oversold
52-week position: The bottom quarter of its range
DCF cross-check: Overvalued

What our data shows for SYK

Our model validated 17 trailing price-to-earnings windows for SYK, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $294.73–$387.02.
The 14-day relative strength index sits at an oversold 30.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for SYK
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent SYK news

TickrTrends' derived news-sentiment signal for SYK is currently leaning positive, computed from recent coverage.

Stryker Corporation (SYK) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript (seekingalpha.com, 2026-09-08)
TickrTrends take: Stryker Corporation's presentation at the Wells Fargo Healthcare Conference provides an opportunity for investors to assess management commentary against the company's current undervalued status according to TickrTrends. For valuation-focused readers, the conference transcript may contain forward guidance, margin expectations, or strategic priorities that could justify whether the current undervalued assessment reflects genuine opportunity or market mispricing within the Healthcare sector. Monitoring how management addresses growth drivers, cost management, and capital allocation during such industry forums can help clarify whether the valuation discount is sustainable or likely to narrow.
Stryker stock drops after CFO remarks (SYK:NYSE) (seekingalpha.com, 2026-09-08)
TickrTrends take: Stryker's recent stock decline following CFO commentary presents a potential opportunity within the context of TickrTrends' undervalued assessment of the company. As a Healthcare sector player, SYK's valuation metrics warrant monitoring to determine whether the market reaction has created a meaningful disconnect between the stock price and the company's underlying fundamentals. Investors focused on valuation should observe whether the CFO's remarks reflect temporary market sentiment or signal changes to the company's financial outlook that would affect its intrinsic value assessment.
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference (manilatimes.net, 2026-09-04)
TickrTrends take: Stryker's participation in the 2026 Wells Fargo Healthcare Conference provides an opportunity for institutional investors and analysts to hear directly from company leadership regarding operational developments and strategic priorities. Given TickrTrends' current undervalued assessment of SYK, investor engagement at major healthcare conferences becomes a potential catalyst for reassessing the stock's valuation metrics and closing any gaps between current market pricing and fundamental value. The conference appearance may offer visibility into how management's forward guidance aligns with or diverges from market expectations in the competitive healthcare sector.

What people are saying

Follow the SYK conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for SYK showed several shifts this week. The DCF cross-check band moved from showing no signal to indicating overvalued status, while the momentum indicator declined from a C rating to no signal, and the RSI zone shifted from neutral to oversold territory. The current valuation verdict for this Healthcare sector company remains undervalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is SYK stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), SYK is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is SYK's TickrTrends verdict?

SYK's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does SYK compare to other Healthcare stocks?

SYK ranks #21 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is SYK overbought or oversold?

SYK's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.

All Healthcare fair-value coverage →

Head-to-head comparisons

SYK vs COO · SYK vs DXCM · SYK vs HQY · SYK vs HSTM · SYK vs ISRG